Compare Global X FTSE Southeast Asia ETF (ASEA) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Global X FTSE Southeast Asia ETF vs Merck & Co., Inc. — how do they compare? Global X FTSE Southeast Asia ETF trades at $20.65, while Merck & Co., Inc. trades at $123.84 (market cap $305.12B). The key difference: Merck & Co., Inc. pays a 2.75% dividend while Global X FTSE Southeast Asia ETF pays none, and Global X FTSE Southeast Asia ETF is trading nearer its 52-week high, Merck & Co., Inc. nearer its low. Which is the better fit depends on your goals.
| ASEA | MRK | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $20.65 | $129.52 |
52-Week Low | $16.31 | $77.60 |
Market Cap | — | $305.12B |
Enterprise Value | — | $348.54B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ASEA stock trades at $20.65, up 0.63% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong momentum with an ADX of 49.11 indicating a trending market. Recent corporate actions include a declared dividend of $0.41 per share scheduled for July 2026. Key support and resistance levels are clustered around $20-$21, suggesting a critical price zone for near-term direction.
The outlook remains cautiously optimistic given technical strength, but fundamental data is currently unavailable for a complete assessment. Risks include potential volatility near key technical levels and reliance on future financial performance disclosures. Investors should await upcoming earnings reports for clarity on valuation and profitability metrics.
Merck (MRK) trades at $123.54, down 1.22% today, with a bullish technical signal from moving averages and a consensus analyst price target of $135.14. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of -$1.28 beating expectations. Revenue grew to $65.01B in 2025, and net income reached $18.25B, reflecting a robust 28.07% profit margin. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, signaling strategic growth initiatives.
The outlook for MRK remains positive driven by earnings momentum and strategic acquisitions, though risks include rising debt levels and competitive pressures. Wall Street sentiment is bullish with 68% buy ratings, but investors should monitor execution of the Terns integration and patent expirations. The stock offers potential upside to the price target with solid fundamentals supporting long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X FTSE Southeast Asia ETF
ASEA tracks the performance of the largest companies in Southeast Asia. It provides exposure to key emerging markets including Singapore, Indonesia, Thailand, and Malaysia, with a heavy focus on financials like DBS Group and Bank Central Asia.
Read more on ASEA →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
